None listed
Conditions
Interventions
None listed
Sponsors
Chonnam National University Hospital Hwasun Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients must have histologically- or cytologically-documented non-small cell lung cancer who present with locally advanced, unresectable (Stage III) disease (according to AJCC 8th edition) 2) Patients must have completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy. 3) Patients must have not progressed following platinum-based chemoradiation therapy. 4) Patients who have received at least one dose of durvalumab between September 2018 and December 2020 in Korea according to the approved label for non-small cell lung cancer.
Exclusion criteria
Exclusion criteria: 1) Patients who have performed surgery for non-small cell lung cancer. 2) Patients with locally advanced non-small cell lung cancer who have progressed after platinum based, chemoradiation therapy. 3) Receipt of any immunotherapy, or investigational drug within 4 weeks prior to the first dose of durvalumab. 4)Patients with off-label indications for current approval in Korea.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median real-world progression-free survival (rwPFS) and rwPFS rate at 1, 2 and 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Median overall survival (OS) and OS rate at 1, 2 and 3 years.;Safety profile ;Treatment profiles ;Real-world progression-free survival(rwPFS) and overall survival(OS) for subgroups of interest demographics | — |
Countries
Korea, Republic of
Contacts
Public ContactIn-Jae Oh
Chonnam National University Hospital Hwasun Hospital
Outcome results
None listed